Q2 2026 Genomma Lab Internacional SAB de CV Earnings Call Transcript
Key Points
- Genomma Lab Internacional SAB de CV (GNMLF) reported a sequential improvement in sales in Mexico, with sell-in declining by only 4.4% compared to previous quarters.
- The company maintained or grew market share across all business units in Mexico despite a contracting market, indicating strong competitive positioning.
- Suerox, a key product, showed significant growth, achieving a double-digit increase in sales and reaching a historic high market share at a leading retailer.
- Gross margin expanded by 106 basis points to 64.6%, driven by productivity gains, despite higher promotional investments.
- The company secured a MXN1.5 billion amortizing term loan with a 10-year maturity, enhancing financial flexibility and allowing for debt refinancing on more favorable terms.
- Net sales declined by 6% year-on-year, largely due to currency translation headwinds from the appreciation of the Mexican peso.
- The United States market faced challenges with a 7.9% decline in local currency sales, impacted by Hispanic retail disruption and a weak cough-and-cold category.
- EBITDA margin declined by 200 basis points to 21.8%, primarily due to operational deleverage on lower volumes.
- Free cash flow decreased by 53% compared to the prior year, reflecting lower operating income and higher working capital requirements.
- The company faces ongoing market headwinds, with all categories in Mexico contracting, including isotonic beverages, OTC, and personal care.
Good day, ladies and gentlemen. Thank you for joining Genomma Lab's second quarter 2026 earnings conference call. (Operator Instructions) As a reminder, this meeting is being recorded and will be available for replay from the Investor Relations section of Genomma's website following the call.
I'll now turn the call over to Christianne Ibanez, Genomma's Head of Investor Relations. Please go ahead.
Thank you and welcome everyone. On today's call are Marco Sparvieri, Chief Executive Officer; and Antonio Zamora, Chief Financial Officer.
Before we get started, I would like to remind you that the remarks today will include forward-looking statements such as the company's financial guidance and expectations, including long-term objectives and forecasts, as well as expectations regarding Genomma's business, products, strategies, demand, and markets. These statements are subject to risks and uncertainties that could cause actual results to differ materially. They are also
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
